To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial...
The recommended dose of Meropenem for Injection is 500 mg given every 8 hours for skin and skin structure infections and 1 g given every 8 hours for intra-abdominal infections. Meropenem for Injection should be administered by intravenous infusion over approximately 15 to 30 minutes. Doses of 1 g may also be administered as an intravenous bolus injection (5 to 20 mL) over approximately 3 to 5 minutes. Dosage shoul...
Meropenem for Injection is supplied in injection vials containing sufficient meropenem to deliver 500 mg or 1 g for intravenous administration, respectively. The dry powder should be stored at controlled room temperature 15 to 25°C (59 to 77°F) [see USP Controlled Room Temperature]. 500 mg Injection Vial (NDC 0781-3265-95) – 10 vials per carton 1 g Injection Vial (NDC 0781-3267-95) – 10 vials per carton
www.fda.gov/medwatchTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Meropenem for Injection is useful as presumptive therapy in the indicated condition (e.g., intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity.
Meropenem for Injection is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes , Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa , Escherichia coli, Proteus mirabilis, Bacteroides fragilis , and Peptostreptococcus species.
Meropenem for Injection is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae , Pseudomonas aeruginosa , Bacteroides fragilis , B. thetaiotaomicron , and Peptostreptococcus species.
Meropenem for Injection is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae‡, Haemophilus influenzae, and Neisseria meningitidis .
‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established.
Meropenem for Injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.
For information regarding use in pediatric patients (3 months of age and older) [see INDICATIONS AND USAGE (1.1, 1.2 , or 1.3); DOSAGE AND ADMINISTRATION (2.3), and ADVERSE REACTIONS (6.1)].
The recommended dose of Meropenem for Injection is 500 mg given every 8 hours for skin and skin structure infections and 1 g given every 8 hours for intra-abdominal infections. Meropenem for Injection should be administered by intravenous infusion over approximately 15 to 30 minutes. Doses of 1 g may also be administered as an intravenous bolus injection (5 to 20 mL) over approximately 3 to 5 minutes.
Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing table below.)
When only serum creatinine is available, the following formula (Cockcroft and Gault equation)5 may be used to estimate creatinine clearance.
Males: Creatinine Clearance (mL/min) =
Weight (kg) x (140– age) |
72 x serum creatinine (mg/dL) |
Females: 0.85 x above value
Creatinine Clearance (mL/min) | Dose (dependent on type of infection) | Dosing Interval |
>50 | Recommended dose (500 mg cSSSI and 1g Intra-abdominal) | Every 8 hours |
>25-50 | Recommended dose | Every 12 hours |
10-25 | One-half recommended dose | Every 12 hours |
<10 | One-half recommended dose | Every 24 hours |
There is inadequate information regarding the use of Meropenem for Injection in patients on hemodialysis or peritoneal dialysis.
For pediatric patients from 3 months of age and older, the Meropenem for Injection dose is 10, 20 or 40 mg/kg every 8 hours (maximum dose is 2 g every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). (See dosing table below.) Pediatric patients weighing over 50 kg should be administered Meropenem for Injection at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 g every 8 hours for intra-abdominal infections and 2 g every 8 hours for meningitis. Meropenem for Injection should be given as intravenous infusion over approximately 15 to 30 minutes or as an intravenous bolus injection (5 to 20 mL) over approximately 3 to 5 minutes.
There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 g) bolus dose.
| Type of Infection | Dose (mg/kg) | Up to a Maximum Dose | Dosing Interval |
|---|---|---|---|
Complicated skin and skin structure | 10 | 500 mg | Every 8 hours |
Intra-abdominal | 20 | 1 g | Every 8 hours |
Meningitis | 40 | 2 g | Every 8 hours |
There is no experience in pediatric patients with renal impairment.
For Intravenous Bolus Administration
Constitute injection vials (500 mg and 1 g) with sterile Water for Injection. (See table below.) Shake to dissolve and let stand until clear.
Vial size | Amount of Diluent Added (mL) | Approximate Withdrawable Volume (mL) | Approximate Average Concentration (mg/mL) |
500 mg | 10 | 10 | 50 |
1 g | 20 | 20 | 50 |
For Infusion
Infusion vials (500 mg and 1 g) may be directly constituted with a compatible infusion fluid. Alternatively, an injection vial may be constituted, then the resulting solution added to an I.V. container and further diluted with an appropriate infusion fluid [see DOSAGE AND ADMINISTRATION ( 2.5 ) and (2.6)].
WARNING: Do not use flexible container in series connections.
Compatibility of Meropenem with other drugs has not been established. Meropenem should not be mixed with or physically added to solutions containing other drugs.
Freshly prepared solutions of Meropenem should be used whenever possible. However, constituted solutions of Meropenem maintain satisfactory potency at controlled room temperature 15-25°C (59-77°F) or under refrigeration at 4°C (39°F) as described below. Solutions of intravenous Meropenem should not be frozen.
Intravenous Bolus Administration
Meropenem for Injection injection vials constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of Meropenem) may be stored for up to 2 hours at controlled room temperature 15-25°C (59-77°F) or for up to 12 hours at 4°C (39°F).
Intravenous Infusion Administration
Stability in Infusion Vials: Meropenem for Injection infusion vials constituted with Sodium Chloride Injection 0.9% (Meropenem concentrations ranging from 2.5 to 50 mg/mL) are stable for up to 2 hours at controlled room temperature 15-25°C (59-77°F) or for up to 18 hours at 4°C (39°F). Infusion vials of Meropenem for Injection constituted with Dextrose Injection 5% (Meropenem concentrations ranging from 2.5 to 50 mg/mL) are stable for up to 1 hour at controlled room temperature 15-25°C (59-77°F) or for up to 8 hours at 4°C (39°F).
Stability in Plastic I.V. Bags: Solutions prepared for infusion (Meropenem concentrations ranging from 1 to 20 mg/mL) may be stored in plastic intravenous bags with diluents as shown below:
Number of Hours Stable at Controlled Room Temperature 15-25°C (59-77°F) | Number of Hours Stable at 4°C (39°F) | |
Sodium Chloride Injection 0.9% | 4 | 24 |
Dextrose Injection 5% | 1 | 4 |
Dextrose Injection 10% | 1 | 2 |
Dextrose and Sodium Chloride Injection 5%/0.9% | 1 | 2 |
Dextrose and Sodium Chloride Injection 5%/0.2% | 1 | 4 |
Potassium Chloride in Dextrose Injection 0.15%/5% | 1 | 6 |
Sodium Bicarbonate in Dextrose Injection 0.02%/5% | 1 | 6 |
Dextrose Injection 5% in Normosol®- M* | 1 | 8 |
Dextrose Injection 5% in Ringers Lactate Injection | 1 | 4 |
Dextrose and Sodium Chloride Injection 2.5%/0.45% | 3 | 12 |
Mannitol Injection 2.5% | 2 | 16 |
Ringers Injection | 4 | 24 |
Ringers Lactate Injection | 4 | 12 |
Sodium Lactate Injection 1/6 N | 2 | 24 |
Sodium Bicarbonate Injection 5% | 1 | 4 |
* NORMOSOL is a registered trademark of Hospira Inc.
Stability in Baxter Minibag Plus® (Manufactured by Baxter, Inc.): Solutions of Meropenem for Injection (Meropenem concentrations ranging from 2.5 to 20 mg/mL) in Baxter Minibag Plus bags with Sodium Chloride Injection 0.9% may be stored for up to 4 hours at controlled room temperatures 15-25°C (59-77°F) or for up to 24 hours at 4°C (39°F). Solutions of Meropenem for Injection (Meropenem concentrations ranging from 2.5 to 20 mg/mL) in Baxter Minibag Plus® bags with Dextrose Injection 5% may be stored up to 1 hour at controlled room temperatures 15-25°C (59-77°F) or for up to 6 hours at 4°C (39°F).
Stability in Plastic Syringes, Tubing and Intravenous Infusion Sets: Solutions of Meropenem for Injection (Meropenem concentrations ranging from 1 to 20 mg/mL) in Water for Injection or Sodium Chloride Injection 0.9% (for up to 4 hours) or in Dextrose Injection 5% (for up to 2 hours) at controlled room temperatures 15-25°C (59-77°F) are stable in plastic tubing and volume control devices of common intravenous infusion sets.
Solutions of Meropenem for Injection (Meropenem for Injection concentrations ranging from 1 to 20 mg/mL) in Water for Injection or Sodium Chloride Injection 0.9% (for up to 48 hours) or in Dextrose Injection 5% (for up to 6 hours) are stable at 4ºC (39ºF) in plastic syringes.
NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Single use clear glass vials containing 500 mg or 1 g (as the trihydrate blend with anhydrous sodium carbonate for constitution) of sterile meropenem powder.
Meropenem for Injection is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to β-lactams.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens.
There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another β-lactam. Before initiating therapy with Meropenem for Injection, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. If an allergic reaction to Meropenem for Injection occurs, discontinue the drug immediately. Serious anaphylactic reactions require immediate emergency treatment with epinephrine, oxygen, intravenous steroids, and airway management, including intubation. Other therapy may also be administered as indicated.
Seizures and other adverse CNS experiences have been reported during treatment with Meropenem for Injection These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis and/or compromised renal function [see ADVERSE REACTIONS (6.1) and DRUG INTERACTIONS (7.2)].
During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with the overall seizure rate being 0.7% (based on 20 patients with this adverse event). All meropenem-treated patients with seizures had pre-existing contributing factors. Among these are included prior history of seizures or CNS abnormality and concomitant medications with seizure potential. Dosage adjustment is recommended in patients with advanced age and/or reduced renal function [see DOSAGE AND ADMINISTRATION (2.2)].
Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity. Anti-convulsant therapy should be continued in patients with known seizure disorders. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anti-convulsant therapy if not already instituted, and the dosage of Meropenem for Injection re-examined to determine whether it should be decreased or the antibiotic discontinued.
Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Antibacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. If administration of Meropenem for Injection is necessary, supplemental anti-convulsant therapy should be considered [see DRUG INTERACTIONS (7.2)].
Clostridium difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Meropenem for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.
Prescribing Meropenem for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
As with other broad-spectrum antibiotics, prolonged use of meropenem may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient is essential. If superinfection does occur during therapy, appropriate measures should be taken.
While Meropenem for Injection possesses the characteristic low toxicity of the beta-lactam group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.
There is inadequate information regarding the use of Meropenem for Injection in patients on hemodialysis or peritoneal dialysis.
Patients receiving Meropenem for Injection on an outpatient basis may develop adverse events such as seizures, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that Meropenem for Injection is well tolerated, patients should not operate machinery or motorized vehicles [see ADVERSE REACTIONS (6.1)].
The following are discussed in greater detail in other sections of labeling:
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adult Patients:
During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with Meropenem for Injection (500 mg or 1000 mg every 8 hours). Deaths in 5 patients were assessed as possibly related to meropenem; 36 (1.2%) patients had meropenem discontinued because of adverse events. Many patients in these trials were severely ill and had multiple background diseases, physiological impairments and were receiving multiple other drug therapies. In the seriously ill patient population, it was not possible to determine the relationship between observed adverse events and therapy with Meropenem for Injection.
The following adverse reaction frequencies were derived from the clinical trials in the 2904 patients treated with Meropenem for Injection.
Local Adverse Reactions
Local adverse reactions that were reported irrespective of the relationship to therapy with Meropenem for Injection were as follows:
Inflammation at the injection site | 2.4% |
Injection site reaction | 0.9% |
Phlebitis/thrombophlebitis | 0.8% |
Pain at the injection site | 0.4% |
Edema at the injection site | 0.2% |
Systemic Adverse Reactions
Systemic adverse reactions that were reported irrespective of the relationship to Meropenem for Injection occurring in greater than 1% of the patients were diarrhea (4.8%), nausea/vomiting (3.6%), headache (2.3%), rash (1.9%), sepsis (1.6%), constipation (1.4%), apnea (1.3%), shock (1.2%), and pruritus (1.2%).
Additional systemic adverse reactions that were reported irrespective of relationship to therapy with Meropenem for Injection and occurring in less than or equal to 1% but greater than 0.1% of the patients are listed below within each body system in order of decreasing frequency:
Bleeding events were seen as follows: gastrointestinal hemorrhage (0.5%), melena (0.3%), epistaxis (0.2%), hemoperitoneum (0.2%), summing to 1.2%.
Body as a Whole: pain, abdominal pain, chest pain, fever, back pain, abdominal enlargement, chills, pelvic pain
Cardiovascular: heart failure, heart arrest, tachycardia, hypertension, myocardial infarction, pulmonary embolus, bradycardia, hypotension, syncope
Digestive System: oral moniliasis, anorexia, cholestatic jaundice/jaundice, flatulence, ileus, hepatic failure, dyspepsia, intestinal obstruction
Hemic/Lymphatic: anemia, hypochromic anemia, hypervolemia
Metabolic/Nutritional: peripheral edema, hypoxia
Nervous System: insomnia, agitation/delirium, confusion, dizziness, seizure, nervousness, paresthesia, hallucinations, somnolence, anxiety, depression, asthenia [see WARNINGS AND PRECAUTIONS (5.2) and (5.10)]
Respiratory: respiratory disorder, dyspnea, pleural effusion, asthma, cough increased, lung edema
Skin and Appendages: urticaria, sweating, skin ulcer
Urogenital System: dysuria, kidney failure, vaginal moniliasis, urinary incontinence
Adverse Laboratory Changes
Adverse laboratory changes that were reported irrespective of relationship to Meropenem for Injection and occurring in greater than 0.2% of the patients were as follows:
Hepatic: increased SGPT (ALT), SGOT (AST), alkaline phosphatase, LDH, and bilirubin
Hematologic: increased platelets, increased eosinophils, decreased platelets, decreased hemoglobin, decreased hematocrit, decreased WBC, shortened prothrombin time and shortened partial thromboplastin time, leukocytosis, hypokalemia
Renal: increased creatinine and increased BUN
NOTE: For patients with varying degrees of renal impairment, the incidence of heart failure, kidney failure, seizure and shock reported irrespective of relationship to Meropenem for Injection, increased in patients with moderately severe renal impairment (creatinine clearance >10 to 26 mL/min) [see DOSAGE AND ADMINISTRATION (2.2), WARNINGS AND PRECAUTIONS (5.8), USE IN SPECIFIC POPULATIONS (8.5) and (8.6), and CLINICAL PHARMACOLOGY (12.3)].
Urinalysis: presence of red blood cells
Complicated Skin and Skin Structure Infections
In a study of complicated skin and skin structure infections, the adverse reactions were similar to those listed above. The most common adverse events occurring in >5% of the patients were: headache (7.8%), nausea (7.8%), constipation (7%), diarrhea (7%), anemia (5.5%), and pain (5.1%). Adverse events with an incidence of >1%, and not listed above, include: pharyngitis, accidental injury, gastrointestinal disorder, hypoglycemia, peripheral vascular disorder, and pneumonia.
Pediatric Patients:
Clinical Adverse Reactions
Meropenem for Injection was studied in 515 pediatric patients (≥ 3 months to < 13 years of age) with serious bacterial infections (excluding meningitis, see next section.) at dosages of 10 to 20 mg/kg every 8 hours. The types of clinical adverse events seen in these patients are similar to the adults, with the most common adverse events reported as possibly, probably, or definitely related to Meropenem for Injection and their rates of occurrence as follows:
Diarrhea | 3.5% |
Rash | 1.6% |
Nausea and Vomiting | 0.8% |
Meropenem for Injection was studied in 321 pediatric patients (> 3 months to < 17 years of age) with meningitis at a dosage of 40 mg/kg every 8 hours. The types of clinical adverse events seen in these patients are similar to the adults, with the most common adverse events reported as possibly, probably, or definitely related to Meropenem for Injection and their rates of occurrence as follows:
Diarrhea | 4.7% |
Rash (mostly diaper area moniliasis) | 3.1% |
Oral Moniliasis | 1.9% |
Glossitis | 1% |
In the meningitis studies, the rates of seizure activity during therapy were comparable between patients with no CNS abnormalities who received meropenem and those who received comparator agents (either cefotaxime or ceftriaxone). In the Meropenem for Injection treated group, 12/15 patients with seizures had late onset seizures (defined as occurring on day 3 or later) versus 7/20 in the comparator arm.
Adverse Laboratory Changes
Laboratory changes seen in the pediatric studies, including the meningitis studies, were similar to those reported in the adult studies.
There is no experience in pediatric patients with renal impairment.
The following adverse reactions have been identified during post-approval use of Meropenem for Injection Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Worldwide post-marketing adverse reactions not otherwise listed in the Adverse Reactions section of this product label and reported as possibly, probably, or definitely drug related are listed within each body system in order of decreasing severity. Hematologic - agranulocytosis, neutropenia, and leukopenia; a positive direct or indirect Coombs test, and hemolytic anemia. Skin-toxic epidermal necrolysis, Stevens-Johnson Syndrome, angioedema, and erythema multiforme.
Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Co-administration of probenecid with meropenem is not recommended.
Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid’s glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. If administration of Meropenem for Injection is necessary, then supplemental anti-convulsant therapy should be considered [see WARNINGS AND PRECAUTIONS (5.3)].
Reproductive studies have been performed with meropenem in rats at doses of up to 1000 mg/kg/day, and cynomolgus monkeys at doses of up to 360 mg/kg/day (on the basis of AUC comparisons, approximately 1.8 times and 3.7 times, respectively, to the human exposure at the usual dose of 1 g every 8 hours). These studies revealed no evidence of impaired fertility or harm to the fetus due to meropenem, although there were slight changes in fetal body weight at doses of 250 mg/kg/day (on the basis of AUC comparisons, 0.4 times the human exposure at a dose of 1 g every 8 hours) and above in rats. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Meropenem for Injection is administered to a nursing woman.
The safety and effectiveness of Meropenem for Injection have been established for pediatric patients ≥ 3 months of age. Use of Meropenem for Injection in pediatric patients with bacterial meningitis is supported by evidence from adequate and well-controlled studies in the pediatric population. Use of Meropenem for Injection in pediatric patients with intra-abdominal infections is supported by evidence from adequate and well-controlled studies with adults with additional data from pediatric pharmacokinetics studies and controlled clinical trials in pediatric patients. Use of Meropenem for Injection in pediatric patients with complicated skin and skin structure infections is supported by evidence from an adequate and well-controlled study with adults and additional data from pediatric pharmacokinetics studies [see INDICATIONS AND USAGE (1.3), DOSAGE AND ADMINISTRATION (2.3), ADVERSE REACTIONS (6.1), CLINICAL PHARMACOLOGY (12.3) and CLINICAL STUDIES (14.3)].
Of the total number of subjects in clinical studies of Meropenem for Injection, approximately 1100 (30%) were 65 years of age and older, while 400 (11%) were 75 years and older. Additionally, in a study of 511 patients with complicated skin and skin structure infections, 93 (18%) were 65 years of age and older, while 38 (7%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects; spontaneous reports and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Meropenem is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
A pharmacokinetic study with Meropenem for Injection in elderly patients has shown a reduction in the plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance [see CLINICAL PHARMACOLOGY (12.3)].
In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.
Intentional overdosing of Meropenem for Injection is unlikely, although accidental overdosing might occur if large doses are given to patients with reduced renal function. The largest dose of meropenem administered in clinical trials has been 2 g given intravenously every 8 hours. At this dosage, no adverse pharmacological effects or increased safety risks have been observed.
Limited post-marketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered. In individuals with normal renal function, rapid renal elimination takes place. Meropenem and its metabolite are readily dialyzable and effectively removed by hemodialysis; however, no information is available on the use of hemodialysis to treat overdosage.
Meropenem for Injection is a sterile, pyrogen-free, synthetic, broad-spectrum, carbapenem antibiotic for intravenous administration. It is (4R,5S,6S)-3- [[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6- [(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate. Its empirical formula is C17H25N3O5S•3H2O with a molecular weight of 437.52. Its structural formula is:
Meropenem for Injection is a white to pale yellow crystalline powder. The solution varies from colorless to yellow depending on the concentration. The pH of freshly constituted solutions is between 7.3 and 8.3. Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether.
When constituted as instructed, each 1 g Meropenem for Injection vial will deliver 1 g of meropenem and 90.2 mg of sodium as sodium carbonate (3.92 mEq). Each 500 mg Meropenem for Injection vial will deliver 500 mg meropenem and 45.1 mg of sodium as sodium carbonate (1.96 mEq) [see DOSAGE AND ADMINISTRATION (2.4)].
Meropenem is an antibacterial drug [see CLINICAL PHARMACOLOGY (12.4)].
At the end of a 30-minute intravenous infusion of a single dose of Meropenem for Injection in healthy volunteers, mean peak plasma concentrations of meropenem are approximately 23 mcg/mL (range 14 to 26) for the 500 mg dose and 49 mcg/mL (range 39 to 58) for the 1 g dose. A 5-minute intravenous bolus injection of Meropenem for Injection in healthy volunteers results in mean peak plasma concentrations of approximately 45 mcg/mL (range 18 to 65) for the 500 mg dose and 112 mcg/mL (range 83 to 140) for the 1 g dose.
Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 mcg/mL at 6 hours after administration.
No accumulation of meropenem in plasma was observed with regimens using 500 mg administered every 8 hours or 1 g administered every 6 hours in healthy volunteers with normal renal function.
The plasma protein binding of meropenem is approximately 2%.
Meropenem penetrates well into most body fluids and tissues including cerebrospinal fluid, achieving concentrations matching or exceeding those required to inhibit most susceptible bacteria. After a single intravenous dose of Meropenem for Injection, the highest mean concentrations of meropenem were found in tissues and fluids at 1 hour (0.5 to 1.5 hours) after the start of infusion, except where indicated in the tissues and fluids listed in the table below.
| Tissue | I.V. Dose (g) | Number of Samples | Mean [mcg/mL or mcg/(g)]* | Range [mcg/mL or mcg/(g)] |
|---|---|---|---|---|
Endometrium | 0.5 | 7 | 4.2 | 1.7-10.2 |
Myometrium | 0.5 | 15 | 3.8 | 0.4-8.1 |
Ovary | 0.5 | 8 | 2.8 | 0.8-4.8 |
Cervix | 0.5 | 2 | 7 | 5.4-8.5 |
Fallopian tube | 0.5 | 9 | 1.7 | 0.3-3.4 |
Skin | 0.5 | 22 | 3.3 | 0.5-12.6 |
Interstitial fluid† | 0.5 | 9 | 5.5 | 3.2-8.6 |
Skin | 1 | 10 | 5.3 | 1.3-16.7 |
Interstitial fluid | 1 | 5 | 26.3 | 20.9-37.4 |
Colon | 1 | 2 | 2.6 | 2.5-2.7 |
Bile | 1 | 7 | 14.6 (3 h) | 4-25.7 |
Gall bladder | 1 | 1 | - | 3.9 |
Peritoneal fluid | 1 | 9 | 30.2 | 7.4-54.6 |
Lung | 1 | 2 | 4.8 (2 h) | 1.4-8.2 |
Bronchial mucosa | 1 | 7 | 4.5 | 1.3-11.1 |
Muscle | 1 | 2 | 6.1 (2 h) | 5.3-6.9 |
Fascia | 1 | 9 | 8.8 | 1.5-20 |
Heart valves | 1 | 7 | 9.7 | 6.4-12.1 |
Myocardium | 1 | 10 | 15.5 | 5.2-25.5 |
CSF (inflamed) | 20 mg/kg‡ | 8 | 1.1 (2 h) | 0.2-2.8 |
40 mg/kg§ | 5 | 3.3 (3 h) | 0.9-6.5 | |
CSF (uninflamed) | 1 | 4 | 0.2 (2 h) | 0.1-0.3 |
There is one metabolite of meropenem that is microbiologically inactive.
In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
Meropenem is primarily excreted unchanged by the kidneys. Approximately 70% (50 – 75%) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Fecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion.
Urinary concentrations of meropenem in excess of 10 mcg/mL are maintained for up to 5 hours after a 500 mg dose.
Pharmacokinetic studies with Meropenem for Injection in patients with renal impairment have shown that the plasma clearance of meropenem correlates with creatinine clearance. Dosage adjustments are necessary in subjects with renal impairment (creatinine clearance 50 mL/min or less) [see DOSAGE AND ADMINISTRATION (2.2) and USE IN SPECIFIC POPULATIONS (8.6)].
Meropenem I.V. is hemodialyzable. However, there is no information on the usefulness of hemodialysis to treat overdosage [see OVERDOSAGE (10)].
A pharmacokinetic study with Meropenem for Injection in patients with hepatic impairment has shown no effects of liver disease on the pharmacokinetics of meropenem.
A pharmacokinetic study with Meropenem for Injection in elderly patients with renal impairment showed a reduction in plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance.
The pharmacokinetics of meropenem in pediatric patients 2 years of age or older are essentially similar to those in adults. The elimination half-life for meropenem was approximately 1.5 hours in pediatric patients of age 3 months to 2 years. The pharmacokinetics are linear over the dose range from 10 to 40 mg/kg.
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. Following administration of probenecid with meropenem, the mean systemic exposure increased 56% and the mean elimination half-life increased 38%. Co-administration of probenecid with meropenem is not recommended.
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1 to 2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes, against which lethal activity is not observed.
Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria.
Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE).
There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) causing reduced bacterial uptake, 2) reduced affinity of the target penicillin-binding-proteins (PBP), 3) increased expression of efflux pump components, and 4) production of antibiotic-destroying enzymes (carbapenemases, metallo-β-lactamases). Localized clusters of infections due to carbapenem-resistant bacteria have been reported in some regions.
Cross resistance is sometimes observed with isolates resistant to other carbapenems.
In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some isolates of Pseudomonas aeruginosa.
Meropenem has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section (1).
Enterococcus faecalis (vancomycin-susceptible isolates only)
Staphylococcus aureus (methicillin-susceptible isolates only)
Streptococcus agalactiae
Streptococcus pneumoniae (penicillin-susceptible isolates only)
Streptococcus pyogenes
Viridans group streptococci
Escherichia coli
Haemophilus influenzae
Klebsiella pneumoniae
Neisseria meningitidis
Pseudomonas aeruginosa
Proteus mirabilis
Bacteroides fragilis
Bacteroides thetaiotaomicron
Peptostreptococcus species
The following in vitro data are available, but their clinical significance is unknown. At least 90% of the following bacteria have exhibited in vitro minimum inhibitory concentrations (MICs) less than or equal to the susceptible breakpoints for meropenem. However, the safety and effectiveness of meropenem in treating clinical infections due to these bacteria have not been established in adequate and well-controlled trials.
Staphylococcus epidermidis (methicillin-susceptible isolates only).
Aeromonashydrophila
Campylobacter jejuni
Citrobacterkoseri(formerly diversus)
Citrobacterfreundii
Enterobacter cloacae
Hafniaalvei
Klebsiella oxytoca
Moraxella catarrhalis
Morganella morganii
Pasteurella multocida
Proteus vulgaris
Serratia marcescens
Bacteroides distasonis
Bacteroides ovatus
Bacteroides uniformis
Bacteroidesureolyticus
Bacteroidesvulgatus
Clostridium difficile
Clostridium perfringens
Eubacteriumlentum
Fusobacterium species
Prevotellabivia
Prevotella intermedia
Prevotella melaninogenica
Porphyromonas asaccharolytica
Propionibacterium acnes
When available, the clinical microbiology laboratory should provide cumulative results of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method. Standardized procedures are based on a dilution method1 ..3 (broth or agar) or equivalent using standardized inoculum concentrations and standardized concentrations of meropenem powder. The MIC values should be interpreted according to the criteria provided in Table 2.
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method 2 ,3 and requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10-mcg of meropenem to test the susceptibility of microorganisms to meropenem. The disk diffusion interpretive criteria are provided in Table 2.
For anaerobic bacteria, the susceptibility to meropenem as MICs can be determined by a standardized test method.2 ,4 The MIC values obtained should be interpreted according to the criteria provided in Table 2.
| Susceptibility Test Result Interpretive Criteria | ||||||
|---|---|---|---|---|---|---|
| Minimum Inhibitory Concentrations (mcg/mL) | Disk Diffusion (zone diameters in mm) | |||||
Pathogen | S | I | R | S | I | R |
Enterobacteriaceae | ≤ 1 | 2 | ≥ 4 | ≥ 23 | 20-22 | ≤ 19 |
Pseudomonasaeruginosa | ≤ 4 | 8 | ≥ 16 | ≥ 16 | 14-15 | ≤ 13 |
Haemophilus influenzae* | ≤ 0.5 | -- | -- | ≥ 20 | -- | -- |
Neisseria meningitidis | ≤ 0.25 | -- | -- | ≥ 30 | -- | -- |
≤ 0.25 | 0.5 | ≥1 | -- | -- | -- | |
Streptococcus agalactiae and Streptococcus pyogenes ,§, | ≤ 0.5 | -- | -- | |||
Anaerobes¶ | ≤ 4 | 8 | ≥ 16 | |||
| ||||||
| ||||||
* The current absence of data on resistant isolates precludes defining any category other than “Susceptible.” If isolates yield MIC results other than susceptible, they should be submitted to a reference laboratory for additional testing.
† Interpretative criteria in Table 2 should only be used for isolates from CSF. For nonmeningitis isolates of Streptococcus pneumoniae a penicillin MIC of ≤0.06 mcg/mL or oxacillin zone ≥20 mm can predict susceptibility to meropenem. MIC testing should be performed on isolates that do not test as susceptible by either of these methods, and on all meningitis S. pneumoniae isolates.
‡ Reliable disk diffusion tests for meropenem do not yet exist for testing streptococci
§ Viridans group streptococci should be tested for meropenem susceptibility using an MIC method
¶ MIC values using either Brucella blood or Wilkins Chalgren agar (former reference medium) are considered equivalent, based upon published in vitro literature and a multicenter collaborative trial for these antimicrobial agents.
A report of Susceptible indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of Intermediate indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Standardized susceptibility test procedures require the use of quality controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard meropenem powder should provide the following range of values noted in Table 3.
| QC Strain | Minimum Inhibitory Concentrations (MICs = mcg/mL) | Disk Diffusion (Zone diameters in mm) |
|---|---|---|
Staphylococcus aureus ATCC 29213 | 0.03-0.12 | |
Staphylococcus aureus ATCC 25923 | 29-37 | |
Streptococcus pneumoniae ATCC 49619 | 0.06-0.25 | 28-35 |
Enterococcus faecalis ATCC 29212 | 2-8 | |
Escherichia coli ATCC 25922 | 0.008-0.06 | 28-34 |
Haemophilusinfluenzae ATCC 49766 | 0.03-0.12 | |
Haemophilusinfluenzae ATCC 49247 | 20-28 | |
Pseudomonas aeruginosa ATCC 27853 | 0.25-1 | 27-33 |
Bacteroides fragilis* ATCC 25285 | 0.03-0.25 | |
Bacteroides thetaiotaomicron ATCC 29741 | 0.125-0.5 | |
Eubacterium lentum ATCC 43055 | 0.125-1 |
* Using the Reference Agar Dilution procedure.
Carcinogenesis studies have not been performed.
Genetic toxicity studies were performed with meropenem using the bacterial reverse mutation test, the Chinese hamster ovary HGPRT assay, cultured human lymphocytes cytogenic assay, and the mouse micronucleus test. There was no evidence of mutagenic potential found in any of these tests.
Reproductive studies were performed with meropenem in rats at doses up to 1000 mg/kg/day, and cynomolgus monkeys at doses up to 360 mg/kg/day (on the basis of AUC comparisons, approximately 1.8 times and 3.7 times, respectively, to the human exposure at the usual dose of 1 g every 8 hours). There was no reproductive toxicity seen.
Adult patients with complicated skin and skin structure infections including complicated cellulitis, complex abscesses, perirectal abscesses, and skin infections requiring intravenous antimicrobials, hospitalization, and surgical intervention were enrolled in a randomized, multi-center, international, double-blind trial. The study evaluated meropenem at doses of 500 mg administered intravenously every 8 hours and imipenem-cilastatin at doses of 500 mg administered intravenously every 8 hours. The study compared the clinical response between treatment groups in the clinically evaluable population at the follow-up visit (test-of-cure). The trial was conducted in the United States, South Africa, Canada, and Brazil. At enrollment, approximately 37% of the patients had underlying diabetes, 12% had underlying peripheral vascular disease and 67% had a surgical intervention. The study included 510 patients randomized to meropenem and 527 patients randomized to imipenem-cilastatin. Two hundred and sixty one (261) patients randomized to meropenem and 287 patients randomized to imipenem-cilastatin were clinically evaluable. The success rates in the clinically evaluable patients at the follow-up visit were 86% (225/261) in the meropenem arm and 83% (238/287) in imipenem-cilastatin arm.
The following table provides the results for the overall as well as subgroup comparisons in clinically evaluable population.
| Success Rate* | ||
|---|---|---|
| Population | Meropenem for Injection n†/N‡ (%) | Imipenem-cilastatin n/N (%) |
Total | 225/261 (86) | 238/287 (83) |
Diabetes mellitus | 83/97 (86) | 76/105 (72) |
No diabetes mellitus | 142/164 (87) | 162/182 (89) |
<65 years of age | 190/218 (87) | 205/241 (85) |
≥65 years of age | 35/43 (81) | 33/46 (72) |
Men | 130/148 (88) | 137/172 (80) |
Women | 95/113 (84) | 101/115 (88) |
* Percent of satisfactory clinical response at follow-up evaluation.
† n=number of patients with satisfactory response.
‡ N=number of patients in the clinically evaluable population or respective subgroup within treatment groups.
The following clinical efficacy rates were obtained, per organism. The values represent the number of patients clinically cured/number of clinically evaluable patients at the post-treatment follow-up visit, with the percent cure in parentheses (Fully Evaluable analysis set).
| MICROORGANISMS* | Meropenem for Injection n†/N‡ (%)§ | Imipenem-cilastatin n/N (%) |
|---|---|---|
Gram-positive aerobes | ||
Staphylococcus aureus, methicillin susceptible | 82/88 (93) | 84/100 (84) |
Streptococcus pyogenes (Group A) | 26/29 (90) | 28/32 (88) |
Streptococcus agalactiae (Group B) | 12/17 (71) | 16/19 (84) |
Enterococcus faecalis | 9/12 (75) | 14/20 (70) |
Streptococcus viridans Group, nos | 11/12 (92) | 5/6 (83) |
Gram-negative aerobes | ||
Escherichia coli | 12/15 (80) | 15/21 (71) |
Pseudomonas aeruginosa | 11/15 (73) | 13/15 (87) |
Proteus mirabilis | 11/13 (85) | 6/7 (86) |
Anaerobes | ||
Bacteroidesfragilis | 10/11 (91) | 9/10 (90) |
Peptostreptococcus species | 10/13 (77) | 14/16 (88) |
* Patients may have more than one pretreatment pathogen.
† n=number of patients with satisfactory response.
‡ N=number of patients in the clinically evaluable population or subgroup within treatment groups.
§ %= Percent of satisfactory clinical response at follow-up evaluation.
The proportion of patients who discontinued study treatment due to an adverse event was similar for both treatment groups (meropenem, 2.5% and imipenem-cilastatin, 2.7%).
One controlled clinical study of complicated intra-abdominal infection was performed in the United States where meropenem was compared with clindamycin/tobramycin. Three controlled clinical studies of complicated intra-abdominal infections were performed in Europe; meropenem was compared with imipenem (two trials) and cefotaxime/metronidazole (one trial).
Using strict evaluability criteria and microbiologic eradication and clinical cures at follow-up which occurred 7 or more days after completion of therapy, the following presumptive microbiologic eradication/clinical cure rates and statistical findings were obtained:
| Treatment Arm | No. evaluable/ No. enrolled (%) | Microbiologic Eradication Rate | Clinical Cure Rate | Outcome |
|---|---|---|---|---|
meropenem | 146/516 (28%) | 98/146 (67%) | 101/146 (69%) | |
imipenem | 65/220 (30%) | 40/65 (62%) | 42/65 (65%) | Meropenem equivalent to control |
cefotaxime/ metronidazole | 26/85 (30%) | 22/26 (85%) | 22/26 (85%) | Meropenem not equivalent to control |
clindamycin/ tobramycin | 50/212 (24%) | 38/50 (76%) | 38/50 (76%) | Meropenem equivalent to control |
The finding that meropenem was not statistically equivalent to cefotaxime/metronidazole may have been due to uneven assignment of more seriously ill patients to the meropenem arm. Currently there is no additional information available to further interpret this observation.
Four hundred forty-six patients (397 pediatric patients ≥ 3 months to < 17 years of age) were enrolled in 4 separate clinical trials and randomized to treatment with meropenem (n=225) at a dose of 40 mg/kg every 8 hours or a comparator drug, i.e., cefotaxime (n=187) or ceftriaxone (n=34), at the approved dosing regimens. A comparable number of patients were found to be clinically evaluable (ranging from 61 to 68%) and with a similar distribution of pathogens isolated on initial CSF culture.
Patients were defined as clinically not cured if any one of the following three criteria were met:
Using the definition, the following efficacy rates were obtained, per organism. The values represent the number of patients clinically cured/number of clinically evaluable patients, with the percent cure in parentheses.
MICROORGANISMS | Meropenem for Injection | COMPARATOR |
S. pneumoniae | 17/24 (71) | 19/30 (63) |
H. influenzae (+)* | 8/10 (80) | 6/6 (100) |
H. influenzae (-/NT)† | 44/59 (75) | 44/60 (73) |
N. meningitidis | 30/35 (86) | 35/39 (90) |
Total (including others) | 102/131 (78) | 108/140 (77) |
Sequelae were the most common reason patients were assessed as clinically not cured.
Five patients were found to be bacteriologically not cured, 3 in the comparator group (1 relapse and 2 patients with cerebral abscesses) and 2 in the meropenem group (1 relapse and 1 with continued growth of Pseudomonas aeruginosa).
The adverse events seen were comparable between the two treatment groups both in type and frequency. The meropenem group did have a statistically higher number of patients with transient elevation of liver enzymes [see ADVERSE REACTIONS (6.1)]. Rates of seizure activity during therapy were comparable between patients with no CNS abnormalities who received meropenem and those who received comparator agents. In the Meropenem for Injection treated group, 12/15 patients with seizures had late onset seizures (defined as occurring on day 3 or later) versus 7/20 in the comparator arm.
With respect to hearing loss, 263 of the 271 evaluable patients had at least one hearing test performed post-therapy. The following table shows the degree of hearing loss between the meropenem-treated patients and the comparator-treated patients.
Degree of Hearing Loss (in one or both ears) | Meropenem n = 128 | Comparator n = 135 |
No loss | 61% | 56% |
20-40 decibels | 20% | 24% |
>40-60 decibels | 8% | 7% |
>60 decibels | 9% | 10% |
Meropenem for Injection is supplied in injection vials containing sufficient meropenem to deliver 500 mg or 1 g for intravenous administration, respectively. The dry powder should be stored at controlled room temperature 15 to 25°C (59 to 77°F) [see USP Controlled Room Temperature].
500 mg Injection Vial (NDC 0781-3265-95) – 10 vials per carton
1 g Injection Vial (NDC 0781-3267-95) – 10 vials per carton
®NORMOSOL is a registered trademark of Hospira Inc.
04-2013
46096142
Manufactured in India by Sandoz Private Ltd.
for Sandoz Inc., Princeton, NJ 08540
NDC 0781-3265-80
Meropenem
for Injection, USP
500 mg* per vial
*Meropenem equivalent
For Intravenous Use Only
Rx only
Contents are Sterile
SANDOZ
NDC 0781-3267-90
Meropenem
for Injection,
USP
1 g* per vial
*Meropenem equivalent
For Intravenous Use Only
Rx only
Contents are Sterile
SANDOZ
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0781-3265-80 | EA - Each | 0781-3265 | 51a28181-18a5-4265-9897-3adb3ccfb3b2 | 1 | 2012-07-24 |
| 0781-3265-95 | EA - Each | 0781-3265 | bc31f5e0-240f-44df-8075-440b3e5aba9d | 1 | 2012-07-24 |
| 0781-3267-90 | EA - Each | 0781-3267 | a0a234d1-336a-4275-b4c2-92b5cd6ee6fd | 1 | 2012-07-24 |
| 0781-3267-95 | EA - Each | 0781-3267 | 4153eecf-ea76-4ffb-bd72-15bb5082934b | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| MEROPENEM | ACTIVE INGREDIENT | FV9J3JU8B1 | 17 | |
| MEROPENEM ANHYDROUS | ACTIVE MOIETY | YOP6PX0BAO | 17 | |
| SODIUM CARBONATE | INACTIVE INGREDIENT | 45P3261C7T | 17 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0781-3265 | 0781-3265-80, 0781-3265-95 |
| 0781-3267 | 0781-3267-90, 0781-3267-95 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MEROPENEM | FV9J3JU8B1 | ACTIB |
| SODIUM CARBONATE | 45P3261C7T | IACT |
| MEROPENEM | FV9J3JU8B1 | ACTIB |
| SODIUM CARBONATE | 45P3261C7T | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | CAPSULE, DELAYED RELEASE / ORAL | 90 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TABLET, FILM COATED / ORAL | 30 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | SUSPENSION / ORAL | 48 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | GUM, CHEWING / BUCCAL | 720 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION / INTRAVENOUS | 241 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1247 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | SOAP / TOPICAL | 0.5 %w/w | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 1248 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 630 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TABLET, EXTENDED RELEASE / ORAL | 80 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TROCHE / ORAL | 375 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TABLET / ORAL | 100 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TABLET / BUCCAL | 20 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | LOZENGE / ORAL | 500 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION / INTRAVASCULAR | ADJ PH | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | SOLUTION / OPHTHALMIC | 0.01 %w/v | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | GUM, CHEWING / ORAL | 240 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TABLET, DELAYED RELEASE / ORAL | 90 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION / INTRAMUSCULAR | 32.4 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION, SOLUTION / INTRAVENOUS | ADJ PH | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION, SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION / INFILTRATION | ADJ PH | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | INJECTION, SOLUTION / INTRAVASCULAR | ADJ PH | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TABLET, EFFERVESCENT / ORAL | 430 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | TABLET / SUBLINGUAL | 8 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | CAPSULE, EXTENDED RELEASE / ORAL | 6 mg | ||
| SODIUM CARBONATE | SODIUM CARBONATE | 45P3261C7T | GRANULE, FOR SUSPENSION / ORAL | 39 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091201-001 | MEROPENEM | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | ||
| A091201-002 | MEROPENEM | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 301d65b070ca… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 1e350fbaab3a… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 8072bd15b7f6… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A091201-001 | MEROPENEM | 500MG/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A091201-002 | MEROPENEM | 1GM/VIAL | INJECTABLE / INJECTION | 2011-03-29 | 74a2ff9319b5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5de5ec96-2d2d-44c6-addf-1bc8034881c0 | a0fcc561-9566-4223-84b3-baa5cf3e0a20 | 2014-05-28 | Warnings, Adverse reactions | a0fcc561-9566-4223-84b3-baa5cf3e0a20 |
Adverse event summaries are temporarily unavailable. Other product information remains available.